secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-005052
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis reports $709M preliminary FY2024 U.S. net product revenue, COO Townsend to depart
--------------------------------------------------------------------------------

- Preliminary FY2024 U.S. net product revenues $709M; SYFOVRE $611M (120% YoY growth), EMPAVELI $98M.
- Cash and equivalents $410M as of Dec 31, 2024, up from $351M a year earlier.
- sNDA for C3G/IC-MPGN expected early 2025; 2H 2025 launch if approved. Phase 3 FSGS and DGF studies planned 2H 2025.
- COO Adam Townsend to depart Feb 21, 2025; David Acheson named EVP of commercial.
- Keli Walbert elected to Board; ex-U.S. workforce reduced by ~40 employees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312525005052/0001193125-25-005052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312525005052/d885806d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer